TruPlan vs InVision Precision Cardiac Amyloid

TruPlan emphasizes 'Fast and intuitive techniques' and 'Easy to Use' with 'Intuitive controls for quick and easy pre-planning' and a 'Simplified LAA workflow'. It also offers remote viewing capabilities through a web viewer. InVision focuses on integrating into existing workflows without requiring new hardware or acquisition changes, and its results are often ready before the study is finished, which is also a strong usability point. However, TruPlan's explicit claims of intuitive controls and simplified workflows for a complex procedural planning task give it a slight edge in direct usability.

InVision Precision Cardiac Amyloid addresses the detection of a life-threatening and often underdiagnosed disease, cardiac amyloidosis, with the aim of earlier detection and improved patient outcomes. It boasts high specificity (99.0%) and a peer-reviewed algorithm published in JAMA Cardiology. TruPlan provides comprehensive pre-procedural planning and post-procedural follow-up for LAAC procedures, which is valuable for procedural success. However, InVision's focus on identifying a critical, often-missed disease with high specificity for earlier intervention provides a more direct and potentially broader clinical impact.

InVision has clear pricing details with a new Medicare NTAP approved for up to $2,275 per eligible inpatient stay and a CPT Category III code for outpatient use, providing a direct pathway for reimbursement. TruPlan's pricing details are less transparent, stating that costs are spread across a broader imaging portfolio, making it harder to assess its direct value proposition. The defined reimbursement pathways for InVision offer a more tangible and immediate financial value for healthcare providers.

TruPlan is part of Circle's cvi42 platform, which is used in over 2,100 hospitals in over 90 countries, indicating a robust and widely adopted enterprise solution. It also offers both standalone and server deployments within hospital infrastructure. InVision offers cloud or on-premise deployment and emphasizes integration with existing PACS and EHR systems, but its overall market penetration and established enterprise footprint appear smaller compared to Circle's extensive reach.

Both tools demonstrate significant innovation in their respective domains. TruPlan offers AI-enabled segmentation and advanced simulation tools for complex LAAC procedures. InVision utilizes AI for the early detection of a challenging-to-diagnose condition (cardiac amyloidosis) from standard echocardiograms, integrating information across multiple views. Both leverage AI to address critical needs in cardiology, making it difficult to definitively pick one as more innovative than the other.

Circle Cardiovascular Imaging (TruPlan's parent company) provides comprehensive documentation including installation guides, user manuals, release notes, and DICOM conformance statements, along with direct support contact information. While InVision emphasizes its integration into clinical workflows and provides information on its trust and security measures, explicit details about ongoing user support and comprehensive documentation are less prominent than for TruPlan.